Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...
Precision medicine approaches for chronic obstructive pulmonary disease (COPD) are lagging, creating gaps in care and leaving ...
Background Pulmonary rehabilitation (PR) is the cornerstone of non-pharmacological treatment for chronic obstructive ...
New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show
A new drug shows promise in reducing the symptoms of COPD, one of the top 10 leading cause of death in the U.S., according to ...
The European Medicines Agency (EMA) has released a new guideline on clinical trials conducted to assess chronic obstructive pulmonary disease (COPD) products, updating an existing guideline regulators ...
10don MSN
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales ...
lung xray_TS_159291221 Clinician awareness of COPD treatment guidelines has increased since 2007. Clinicians report multiple barriers preventing the diagnosis of chronic obstructive pulmonary disease ...
Credit: Scott Bodell/MedicalImages.com The authors outline preventative pharmacologic therapies for COPD exacerbations and a patient-tailored approach to management. Chronic obstructive pulmonary ...
David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results